

| | | |
|--|------------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | 10502080 |
| | Filing Date | 2004-10-08 |
| | First Named Inventor | BOWEN, J. Phillip |
| | Art Unit | 1612 |
| | Examiner Name | Brian GULLEDGE |
| | Attorney Docket Number | B40-002 |

U.S.PATENTS

| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|---------------|------------------------|------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² ¹ | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|--|------------------------|------------------|---|--|--------------------------|
| | 1 | | | | | | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

| | | | |
|--------------------|---------|--|----------------|
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|--|----------------|

| | | | |
|---|---------|----------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | | Application Number | 10502080 |
| | | Filing Date | 2004-10-08 |
| | | First Named Inventor | BOWEN, J. Phillip |
| | | Art Unit | 1612 |
| | | Examiner Name | Brian GULLEDGE |
| Attorney Docket Number | B40-002 | | |

| | | | |
|-------|---|--|--------------------------|
| /PEZ/ | 1 | JOHNSON JI et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer 2001, 84(10):1424-1431. | <input type="checkbox"/> |
| | 2 | LIU B et al., Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells. Mol. Vis. 2010, 16:184-193. | <input type="checkbox"/> |
| | 3 | PHUNG TL et al., Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res. 2007, 67(11):5070-5075. Erratum in: Cancer Res. 2007, 67(13):6528. | <input type="checkbox"/> |
| | 4 | SUGGITT M et al., Fifty years of preclinical anticancer drug screening: empirical to target-driven approaches. Clinical Cancer Research 2005, 11:971-981. | <input type="checkbox"/> |
| | 5 | TARNAWSKI AS et al., PTEN silencing reverses aging-related impairment of angiogenesis in microvascular endothelial cells. Biochem Biophys Res Commun 2010, 394(2):291-296. | <input type="checkbox"/> |
| | 6 | VOSKOGLOU-NOMIKOS T et al., Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clinical Cancer Research 2003, 9:4227-4239. | <input type="checkbox"/> |
| | 7 | WANG D et al., Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999, 59(7):1464-1472. | <input type="checkbox"/> |
| | 8 | ZHONG H et al., Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60(6):1541-1545. | <input type="checkbox"/> |
| | 9 | | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Paul Zarek/ | Date Considered | 06/28/2011 |
|--------------------|--------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|-------------------|
| Application Number | 10502080 |
| Filing Date | 2004-10-08 |
| First Named Inventor | BOWEN, J. Phillip |
| Art Unit | 1612 |
| Examiner Name | Brian GULLEDGE |
| Attorney Docket Number | B40-002 |

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.